Transforming Gum Health

PerioTrap develops selective active ingredients that block the virulence of periodontitis pathogens – without harming the oral microbiome. Our goal: a new product category bridging cosmetics and medicine, based on genuine biotechnology.

{"type":"root","children":[{"type":"heading","level":1,"children":[{"type":"text","value":" A new class of active ingredients for gum health"}]}]}

Periodontitis is one of the most common chronic diseases worldwide – and until now, a precise, microbiome-friendly approach has been lacking. PerioTrap develops active ingredients that specifically block the disease-causing mechanisms of P. gingivalis . This creates the foundation for modern prophylaxis and care products that modulate, rather than eliminate, the disease.

Learn more about the Technology

"We are bringing biotechnology to where it has been lacking for decades – to dentistry."

Pierre Tangermann

CEO PerioTrap Pharmaceuticals GmbH

Thinking from the root cause: precision instead of broad approaches

Antiseptics and antibiotics act non-specifically and attack the entire microbiome. PerioTrap takes a fundamentally different approach: We selectively neutralize pathogens, protect beneficial bacteria, and thus enable a sustainable balance in the oral ecosystem. Based on this, we develop products for the mass market, for professionals – and, in the future, for regulated applications.

Learn more

"The future of periodontitis prevention lies in the targeted modulation of the microbiome, not in its destruction."

Dr. Nadine Taudte

Senior Scientist at PerioTrap

PerioTrap® Microbiome Toothpaste – Daily Precision Care

Our first commercial application of PerioTrap® technology: A microbiome-friendly toothpaste that blocks the disease-causing mechanisms of P. gingivalis without harming the beneficial oral flora. Developed for the mass market – scientifically differentiated, safe, and suitable for daily use.

for home use

Go to the Consumer website

PerioTrap® Prophylaxis Care Gel – for professional use

This care gel was specially developed for dental prophylaxis. It supports the reduction of pro-inflammatory factors, protects the microbiome, and offers patients a precise, locally acting complement to professional gum treatment. Ideal for use in practice – before, during, and after periodontal therapy.

for Clinic use

Go to the Pro website

News & Publications
Mikrobiom-Schutz: Neue Technologie bringt Fortschritt für Zahngesundheit

Mikrobiom-Schutz: Neue Technologie bringt Fortschritt für Zahngesundheit

PerioTrap startet 2025 mit orazen™ – die neue Mikrobiom-Zahnpasta und ein Prophylaxe-Gel setzen statt auf breite Keimabtötung auf selektive Virulenzhemmung und schützen gezielt vor Parodontitis.

Wissenschaftliche Publikationen

Title: Effect of a bacterial glutaminyl cyclase inhibitor on multi-species biofilms.

Authors: Eick, Sigrun, Taudte, Nadine, Ramsbeck, Daniel, Magdoń, Anna, Sculean, Anton, Potempa, Jan, Buchholz, Mirko
Year of publication: 2025
Journal: Front. Oral Heal. 6, 1716625.

Link: DOI

Title: Novel small molecule targeting PgQC reduces Porphyromonas gingivalis virulence

Authors: Nadine Taudte, Linda Liebe, Nadine Jänckel, Daniel Ramsbeck, Stephan Schilling, Jan Potempa, Sigrun Eick, Mirko Buchholz
Year of publication: 2025
Journal: bioRxiv 2025.09.30.679452.

Link: DOI

Title: Mammalian-like type II glutaminyl cyclases in Porphyromonas gingivalis and other oral pathogenic bacteria as targets for treatment of periodontitis

Authors:
Taudte, Nadine; Linnert, Miriam; Rahfeld, Jens‑Ulrich; Piechotta, Anke; Ramsbeck, Daniel; Buchholz, Mirko; Kolenko, Petr; Parthier, Christoph; Houston, John A.; Veillard, Florian; Eick, Sigrun; Potempa, Jan; Schilling, Stephan; Demuth, Hans‑Ulrich; Stubbs, Matthew T.
Year of publication: 2021
Journal: Journal of Biological Chemistry 296, 100263.

Link: DOI

Title: Tetrahydroimidazo[4,5-c]pyridine-Based Inhibitors of Porphyromonas gingivalis Glutaminyl Cyclase

Authors: Daniel Ramsbeck, Nadine Taudte, Nadine Jänckel, Stefanie Strich, Jens-Ulrich Rahfeld, Mirko Buchholz2
Year of publication: 2021
Journal: Pharmaceuticals 2021, 14(12). 1206.

Link: DOI

Title: Expression of human and Porphyromonas gingivalis glutaminyl cyclases in periodontitis and rheumatoid arthritis–A pilot study

Authors: Philip Bendera, Andreas Eggera, Martin Westermann,Nadine Taudte, Anton Sculean, Jan Potempa, Burkhard Möller, Mirko Buchholz, Sigrun Eick
Year of publication: 2019
Journal: 
Archive Oral Biology. 97, 223–230.

Link: DOI